Cellular mechanism of vasculo-protection induced by polyphenols on the endothelium;Mécanismes de la protection cardiaque et vasculaire des polyphénols au niveau de l'endothélium

Annales de Cardiologie et d'Angeiologie

Volumn 51, Issue 6, 2002, Pages 304-315

  Martin, S ^a   Andriantsitohaina, R ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Apoptosis; Migration; Proliferation; Red wine; Vascular remodeling

Indexed keywords

ALCOHOL; POLYPHENOL;

ALCOHOL CONSUMPTION; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; DIET; FRUIT; GENE EXPRESSION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; NONHUMAN; PATHOGENESIS; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VEGETABLE; WINE;

ANIMALS; APOPTOSIS; BIOPOLYMERS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PHENOLS; RATS; VASOCONSTRICTION; VASODILATION; WINE;

EID: 0036956359     PISSN: 00033928     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-3928(02)00138-5     Document Type: Article

References (87)

1. St Leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet 1979;1:1017-20.
2. Tjonneland A, Gronbaek M, Stripp C, Overvad K. Wine intake and diet in a random sample of 48763 Danish men and women. Am J Clin Nutr 1999;69:49-54.
3. Renaud SC, Gueguen R, Schenker J, d'Houtaud A. Alcohol and mortality in middle-aged men from eastern France. Epidemiology 1998;9:184-8.
4. Masquelier J. Wine in nutrition. Aliment Vie 1965;53:261-70.
5. Van Tol A, van der Gaag MS, Scheek LM, van Gent T, Hendriks HF. Changes in postprandial lipoproteins of low and high density caused by moderate alcohol consumption with dinner. Atherosclerosis 1998;141(Suppl 1):S101-3.
6. Zoucas E, Bergqvist D, Goransson G, Bengmark S. Effect of acute ethanol intoxication on primary haemostasis, coagulation factors and fibrinolytic activity. Eur Surg Res 1982;14:33-44.
7. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998;56:317-33.
8. Andriambeloson E, Kleschyov AL, Muller B, Beretz A, Stoclet JC, Andriantsitohaina R. Nitric oxide production and endothelium-dependent vasorelaxation induced by wine polyphenols in rat aorta. Br J Pharmacol 1997;120:1053-8.
9. Andriambeloson E, Magnier C, Haan-Archipoff G, Lobstein A, Anton R, Beretz A, et al. Natural dietary polyphenolic compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. J Nutr 1998;128:2324-33.
10. Andriambeloson E, Stoclet JC, Andriantsitohaina R. Mechanism of endothelial nitric oxide-dependent vasorelaxation induced by wine polyphenols in rat thoracic aorta. J Cardiovasc Pharmacol 1999;33:248-54.
11. Bernatova I, Pechanova O, Babal P, Kysela S, Stvrtina S, Andriantsitohaina R. Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am J Physiol Heart Circ Physiol 2002;282:H942-8.
12. Diebolt M, Bucher B, Andriantsitohaina R. Wine polyphenols decrease blood pressure, improve NO vasodilatation, and induce gene expression. Hypertension 2001;38:159-65.
13. Martin S, Diebolt M, Andriantsitohaina R. Moderate alcohol consumption and cardiovascular diseases. Pathol Biol (Paris) 2001;49:769-74.
14. Martin S, Andriambeloson E, Takeda K, Andriantsitohaina R. Red wine polyphenols increase calcium in bovine aortic endothelial cells: a basis to elucidate signalling pathways leading to nitric oxide production. Br J Pharmacol 2002;135:1579-87.
15. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
16. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61.
17. Brown AA, Hu FB. Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 2001;73:673-86.
18. Boulanger CM, Vanhoutte PM. Facteurs vasoactifs produits par l'endothélium. In: Flammarion, editor. Biologie et pathologie du cœur et des vaisseaux. Paris: GRRC; 2002. p. 447-53.
19. Akimoto S, Mitsumata M, Sasaguri T, Yoshida Y. Laminar shear stress inhibits vascular endothelial cell proliferation by inducing cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1. Circ Res 2000;86:185-90.
20. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. Circulation 1997;95:1760-3.
21. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-44.
22. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-4.
23. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
24. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
25. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101:731-6.
26. Richard V, Thulliez C. Dysfonction endothéliale. In: Flammarion, editor. Biologie et pathologie du cœur et des vaisseaux. Paris: GRRC; 2002. p. 381-90.
27. Bode-Boger SM, Boger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996;93:85-90.
28. Hamon M, Vallet B, Bauters C, Wernert N, McFadden EP, Lablanche JM, et al. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994;90:1357-62.
29. Marks DS, Vita JA, Folts JD, Keaney Jr JF, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 1995;96:2630-8.
30. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4.
31. Chaux A, Ruan XM, Fishbein MC, Ouyang Y, Kaul S, Pass JA, et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998;115:604-12.
32. Chen C, Hanson SR, Keefer LK, Saavedra JE, Davies KM, Hutsell TC, et al. Boundary layer infusion of nitric oxide reduces early smooth muscle cell proliferation in the endarterectomized canine artery. J Surg Res 1997;67:26-32.
33. Hanson SR, Hutsell TC, Keefer LK, Mooradian DL, Smith DJ. Nitric oxide donors: a continuing opportunity in drug design. Adv Pharmacol 1995;34:383-98.
34. Pulfer SK, Ott D, Smith DJ. Incorporation of nitric oxide-releasing crosslinked polyethyleneimine microspheres into vascular grafts. J Biomed Mater Res 1997;37:182-9.
35. Smith DJ, Chakravarthy D, Pulfer S, Simmons ML, Hrabie JA, Citro ML, et al. Nitric oxide-releasing polymers containing the [N(O)NO]- group. J Med Chem 1996;39:1148-56.
36. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, et al. Snitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A 1992;89:444-8.
37. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A 1995;92:1137-41.
38. Mazza G. Anthocyanins in grapes and grape products. Crit Rev Food Sci Nutr 1995;35:341-71.
39. Harborne JB. The anthocyanin pigments. Comparative Biochemistry of the flavonoides. New York: Academic press; 1967 p. 1-30.
40. Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 1976;24:117-91.
41. Pierpoint WS. Flavonoids in the human diet. Prog Clin Biol Res 1986;213:125-40.
42. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11.
43. Hertog MG, Hollman PC, Katan MB, Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 1993;20:21-9.
44. Justesen U, Knuthsen P, Leth T. Determination of plant polyphenols in Danish foodstuffs by HPLC-UV and LC-MS detection. Cancer Lett 1997;114:165-7.
45. Paganga G, Rice-Evans CA. The identification of flavonoids as glycosides in human plasma. FEBS Lett 1997;401:78-82.
46. Matsumoto H, Inaba H, Kishi M, Tominaga S, Hirayama M, Tsuda T. Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms. J Agric Food Chem 2001;49:1546-51.
47. Middleton Jr E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000;52:673-751.
48. Osakabe N, Yasuda A, Natsume M, Takizawa T, Terao J, Kondo K. Catechins and their oligomers linked by C4 → C8 bonds are major cacao polyphenols and protect low-density lipoprotein from oxidation in vitro. Exp Biol Med (Maywood) 2002;227:51-6.
49. lijima K, Yoshizumi M, Hashimoto M, Kim S, Eto M, Ako J, et al. Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gene. Circulation 2000;101:805-11.
50. Wollny T, Aiello L, Di Tommaso D, Bellavia V, Rotilio D, Donati MB, et al. Modulation of haemostatic function and prevention of experimental thrombosis by red wine in rats: a role for increased nitric oxide production. Br J Pharmacol 1999;127:747-55.
51. Flesch M, Schwarz A, Bohm M. Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:H1183-90.
52. Burns J, Gardner PT, O'Neil J, Crawford S, Morecroft I, McPhail DB, et al. Relationship among antioxidant activity, vasodilation capacity, and phenolic content of red wines. J Agric Food Chem 2000;48:220-30.
53. Jimenez R, Andriambeloson E, Duarte J, Andriantsitohaina R, Jimenez J, Perez-Vizcaino F, et al. Involvement of thromboxane A2 in the endothelium-dependent contractions induced by myricetin in rat isolated aorta. Br J Pharmacol 1999;127:1539-44.
54. Fitzpatrick DF, Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am J Physiol 1993;265:H774-8.
55. Matsuo S, Nakamura Y, Takahashi M, Ouchi Y, Hosoda K, Nozawa M. Effect of red wine and ethanol on production of nitric oxide in healthy subjects. Am J Cardiol 2001;87:1029-31.
56. Ramasamy S, Drummond GR, Ahn J, Storek M, Pohl J, Parthasarathy S. Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells. Mol Pharmacol 1999;56:116-23.
57. + current in vascular endothelial cells. Cardiovasc Res 2000;45:1035-45.
58. 2+ ATPase by quercetin. J Biol Chem 1996;271:24517-25.
59. Lugnier C, Schini VB. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 1990;39:75-84.
60. Beretz A, Anton R, Cazenave JP. The effects of flavonoids on cyclic nucleotide phosphodiesterases. Prog Clin Biol Res 1986;213:281-96.
61. Beretz A, Briancon-Scheid F, Stierle A, Corre G, Anton R, Cazenave JP. Inhibition of human platelet cyclic AMP phosphodiesterase and of platelet aggregation by a hemisynthetic flavonoid, amentoflavone hexaacetate. Biochem Pharmacol 1986;35:257-62.
62. Paquay JB, Haenen GR, Stender G, Wiseman SA, Tijburg LB, Bast A. Protection against nitric oxide toxicity by tea. J Agric Food Chem 2000;48:5768-72.
63. Corder R, Douthwaite JA, Lees DM, Khan NQ, Viseu Dos Santos AC, Wood EG. Endothelin-1 synthesis reduced by red wine. Nature 2001;414:863-4.
64. Zhao X, Gu Z, Attele AS, Yuan CS. Effects of quercetin on the release of endothelin, prostacyclin and tissue plasminogen activator from human endothelial cells in culture. J Ethnopharmacol 1999;67:279-85.
65. Igura K, Ohta T, Kuroda Y, Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 2001;171:11-6.
66. Szende B, Tyihak E, Kiraly-Veghely Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 2000;32:88-92.
67. Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001;15:1798-800.
68. Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 1999;59:2596-601.
69. Bruder JL, Hsieh TT, Lerea KM, Olson SC, Wu JM. Induced cytoskeletal changes in bovine pulmonary artery endothelial cells by resveratrol and the accompanying modified responses to arterial shear stress. BMC Cell Biol 2: 1 2001;2:1.
70. Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 2001;186:1-10.
71. Maeda-Yamamoto M, Kawahara H, Tahara N, Tsuji K, Hara Y, Isemura M. Effects of tea polyphenols on the invasion and matrix metalloproteinases activities of human fibrosarcoma HT1080 cells. J Agric Food Chem 1999;47:2350-4.
72. Leppert D, Lindberg RL, Kappos L, Leib SL. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001;36:249-57.
73. Rogers JC, Williams Jr DL. Kaempferol inhibits myosin light chain kinase. Biochem Biophys Res Commun 1989;164:419-25.
74. Vieira O, Escargueil-Blanc I, Meilhac O, Basile JP, Laranjinha J, Almeida L, et al. Effect of dietary phenolic compounds on apoptosis of human cultured endothelial cells induced by oxidized LDL. Br J Pharmacol 1998;123:565-73.
75. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
76. Feng AN, Chen YL, Chen YT, Ding YZ, Lin SJ. Red wine inhibits monocyte chemotactic protein-1 expression and modestly reduces neointimal hyperplasia after balloon injury in cholesterol-Fed rabbits. Circulation 1999;100:2249-54.
77. Duarte J, Perez-Palencia R, Vargas F, Ocete MA, Perez-Vizcaino F, Zarzuelo A, et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 2001;133:117-24.
78. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A 1993;90:2690-4.
79. Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, et al. Efficacy of Daflon 500mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology 1997;48:77-85.
80. Guilhou JJ, Fevrier F, Debure C, Dubeaux D, Gillet-Terver MN, Guillot B, et al. Benefit of a 2-month treatment with a micronized, purified flavonoidic fraction on venous ulcer healing. A randomized, double-blind, controlled versus placebo trial. Int J Microcirc Clin Exp 1997;17(Suppl 1):21-6.
81. Menyhelyi G, Acsady G, Hetenyi A, Dubeaux D, Rado G. The chronobiology and clinical efficacy of Daflon in the treatment of chronic venous insufficiency. Ter Arkh 1997;69:46-8.
82. Pecking AP, Fevrier B, Wargon C, Pillion G. Efficacy of Daflon 500mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997;48:93-8.
83. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr 1995;61:549-54.
84. 2+- oxidizability: possible explanation by phenolic location. Eur J Clin Nutr 1997;51:682-90.
85. Day AP, Kemp HJ, Bolton C, Hartog M, Stansbie D. Effect of concentrated red grape juice consumption on serum antioxidant capacity and low-density lipoprotein oxidation. Ann Nutr Metab 1997;41:353-7.
86. Rice-Evans C, Miller N. Measurement of the antioxidant status of dietary constituents, low density lipoproteins and plasma. Prostaglandins Leukot Essent Fatty Acids 1997;57:499-505.
87. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996;2:659-68.